The structure-function relationship of oncogenic LMTK3 by Ditsiou, Angeliki et al.
The structure­function relationship of oncogenic LMTK3
Article  (Published Version)
http://sro.sussex.ac.uk
Ditsiou, Angeliki, Cilibrasi, Chiara, Simigdala, Nikiana, Harris, Leanne, Vella, Viviana, Gagliano, 
Teresa, Iachini, Maria Chiara, Simon, Thomas, Zhou, Lihong, Hassell-Hart, Storm, Pearl, 
Laurence H, Roe, S Mark, Spencer, John, Prodromou, Chrisostomos, Giamas, Georgios et al. 
(2020) The structure-function relationship of oncogenic LMTK3. Science Advances, 6 (46). pp. 1-
19. ISSN 2375-2548 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/95103/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
Ditsiou et al., Sci. Adv. 2020; 6 : eabc3099     13 November 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
1 of 19
C A N C E R
The structure-function relationship of oncogenic LMTK3
Angeliki Ditsiou1, Chiara Cilibrasi1, Nikiana Simigdala2, Athanasios Papakyriakou3, 
Leanne Milton-Harris1, Viviana Vella1, Joanne E. Nettleship4,5, Jae Ho Lo6, Shivani Soni6, 
Goar Smbatyan6, Panagiota Ntavelou2, Teresa Gagliano1*, Maria Chiara Iachini1,  
Sahir Khurshid7, Thomas Simon1, Lihong Zhou8, Storm Hassell-Hart9, Philip Carter10, 
Laurence H. Pearl8, Robin L. Owen11, Raymond J. Owens4,5,12, S. Mark Roe8, Naomi E. Chayen7, 
Heinz-Josef Lenz6, John Spencer9, Chrisostomos Prodromou1, Apostolos Klinakis2, 
Justin Stebbing10†, Georgios Giamas1†‡
Elucidating signaling driven by lemur tyrosine kinase 3 (LMTK3) could help drug development. Here, we solve the 
crystal structure of LMTK3 kinase domain to 2.1Å resolution, determine its consensus motif and phosphoproteome, 
unveiling in vitro and in vivo LMTK3 substrates. Via high-throughput homogeneous time-resolved fluorescence 
screen coupled with biochemical, cellular, and biophysical assays, we identify a potent LMTK3 small-molecule inhib-
itor (C28). Functional and mechanistic studies reveal LMTK3 is a heat shock protein 90 (HSP90) client protein, requir-
ing HSP90 for folding and stability, while C28 promotes proteasome-mediated degradation of LMTK3. Pharmaco-
logic inhibition of LMTK3 decreases proliferation of cancer cell lines in the NCI-60 panel, with a concomitant increase 
in apoptosis in breast cancer cells, recapitulating effects of LMTK3 gene silencing. Furthermore, LMTK3 inhibition 
reduces growth of xenograft and transgenic breast cancer mouse models without displaying systemic toxicity at 
effective doses. Our data reinforce LMTK3 as a druggable target for cancer therapy.
INTRODUCTION
Protein kinases play a pivotal role in regulating intracellular signal 
transduction pathways involving almost every aspect of cell activity 
including proliferation, survival, differentiation, apoptosis, metab-
olism, angiogenesis, immune surveillance, and motility. Perturba-
tion of their signaling affects their activities, which contributes to 
human diseases including malignancies (1–3). Targeted therapies 
against kinases have improved the clinical outcome of patients in 
the past decade. However, resistance to these treatments often de-
velops, largely because of the aberrant activation of other kinases 
having a complementary or compensatory function (1, 3), and we 
have shown redundancy in kinase signaling in broad networks (4).
The oncogenic role of lemur tyrosine kinase 3 (LMTK3) has 
been established over the past years, supported by mechanistic and 
translational data in different tumor types and settings in vitro and 
in vivo (5–16). LMTK3 has been originally identified via a kinome 
screening as a regulator of estrogen receptor  (ER) in breast 
cancer (BC) (5), able to protect it from ubiquitin-mediated prote-
asomal degradation. Follow-up studies have demonstrated that 
LMTK3 is overexpressed in more aggressive forms of BC, and it is 
implicated in endocrine (9) and chemotherapy resistance (10) in 
BC. While high LMTK3 mRNA expression has been reported to be 
an independent poor prognostic factor in patients with ER+ BC 
(17), immunohistochemistry (IHC) analysis has further revealed 
that tumors overexpressing human epidermal growth factor re-
ceptor 2 (HER2) are more likely to be LMTK3 positive, while triple- 
negative BC (TNBC) tumors have high cytoplasmic expression of 
LMTK3 (8). Furthermore, the involvement of LMTK3 in invasion 
(12), migration (12), chromatin remodeling (13), and microRNA 
biogenesis (6) in BC has also been documented. Since LMTK3 has 
been proposed as a potential therapeutic target in BC and con-
sidering its involvement in other tumors, there is a pressing need to 
further decipher the signaling pathways in which LMTK3 is impli-
cated in and identify potent, selective, and cell-permeable small- 
molecule inhibitors that can be used to enable pathway investigation 
and, in doing so, also establish onward tractability for future trans-
lational activities.
Radiolabeled biochemical assays using a positional scanning 
peptide library (PSPL) (18) resulted in elucidation of the LMTK3 
phosphorylation consensus sequence and the subsequent identifi-
cation of heat shock protein 27 (HSP27) as an in vitro phos-
phorylation substrate of LMTK3. Moreover, by using a stable 
isotope labeling by amino acids in cell culture (SILAC) quantitative 
phosphoproteomics approach, we uncovered various LMTK3- 
modulated phospho-proteins (direct and/or indirect targets) that 
can shed light on the biologic functions regulated by LMTK3. To 
aid research on LMTK3 as a therapeutic target, we report the 
three-dimensional x-ray crystal structure of LMTK3 alongside 
methods for the production and purification of the recombinant 
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protein. Using robust in vitro and cell-based screening assay and 
selectivity assay combined with biophysical analyses, we identified 
and characterized a small-molecule adenosine 5′-triphosphate 
(ATP)–competitive LMTK3 inhibitor (C28) that acts by degrading 
LMTK3 via the ubiquitin-proteasome pathway. Our data revealed 
LMTK3 to be an HSP90-CDC37 (cell division cycle 37) client protein, 
which was able to phosphorylate CDC37 in vitro. Chemical inhibi-
tion of LMTK3 provided a notable therapeutic effect as demonstrated 
in a panel of 60 cancer cell lines [National Cancer Institute Develop-
mental Therapeutics Program (NCI-DTP)] and suppressed tumor 
growth of BC xenograft and transgenic mice models. Together, we 
report the crystal structure and phosphorylation motif of LMTK3 
and identify an LMTK3 inhibitor that confers cytotoxic and antitumor 
effects. We believe that further development and optimization of 
LMTK3 inhibitors based on this study could have prospective value 
to patients with cancer, and we provide the preclinical data to take 
the development of these compounds forward.
RESULTS
Crystallization and overview of the LMTK3 structure
LMTK3 shares structural and sequence similarities to the kinase 
domains of the transmembrane receptor epidermal growth factor 
receptor (EGFR also known as ERBB1 and HER1), insulin receptor 
(INSR), and the Janus kinase (JAK), a family of intracellular, non-
receptor tyrosine kinases (19–21). The activation loop of INSR has 
three tyrosine residues (22), like the kinase domain of LMTK3. Us-
ing equivalent LMTK3 residues (amino acids 130 to 413) to INSR 
kinase and the other kinases in this analysis, the sequence identity 
for EGFR, INSR, and JAK1 with LMTK3 is 26, 34, and 27%, respec-
tively, while the sequence similarity is 45, 49, and 42%, respectively, 
when calculated using “Ident and Sim” (fig. S1) (23). The structure 
of human EGFR kinase domain in complex with the nonhydrolyz-
able ATP analog adenylyl-imidodiphosphate (AMP-PNP), the kinase 
domain of JAK1 in complex with adenosine 5´-diphosphate (ADP), 
and the kinase domain of INSR have been previously determined 
(21, 22, 24). Here, we solved the crystal structure of the LMTK3 
catalytic domain (from now on referred as LMTK3cat) to 2.1-Å res-
olution using a recombinant protein comprising residues 134 to 444 
(crystallization statistics are shown in table S1). The overall fold of 
the LMTK3 kinase domain (Fig. 1, A and B) was similar to that of 
other kinases. We find that LMTK3cat adopts an inactive confor-
mation, with the key DYG motif (more commonly DFG motif) 
stabilized in the “DYG-out” conformation, while comparative studies 
with either JAK1 (25) [Protein Data Bank (PDB) 5KHW; Fig. 1C] or 
EGFR (PDB 5CNO; Fig. 1D) suggested that key features and resi-
dues of the LMTK3 kinase are all conserved. This would allow for 
its activation (fig. S1), following conformational changes due to 
phosphorylation of the activation loop and repositioning of the 
DYG motif, that lead to the binding and hydrolysis of ATP.
In LMTK3, we found that Tyr314 of the DYG motif, more com-
monly DFG in kinases, occupies the equivalent space of the adenine 
ring of ATP and thus maintains the integrity of the C-spine, a series 
of residues that connect the F helix to the N-terminal lobe (fig. S2, 
A to D) (26, 27). Only a few other kinases in the human kinome 
such as leucine-rich repeat kinase 1/2 (LRRK1/2), NEK9, and 
VRK1/2 have a Tyr at this position. Tyrosine in this conformation 
is stabilized by a number of hydrogen bonds (fig. S2E). Thus, 
although EGFR and LMTK3 show a degree of homology, the 
detailed mechanisms by which they achieve an inactive state and pre-
vent ATP binding differ in detail. The DYG motif is closely associated 
with the HSD motif, usually HRD for most kinases, through a series 
of hydrogen bonds that particularly involve the catalytic Asn300, which 
is normally involved in magnesium ion coordination (fig. S2F). How-
ever, within the activation loop, there are potentially three tyrosine 
autophosphorylation or phosphorylation activation sites at Tyr321, 
Tyr325, and Tyr326 (fig. S2G), which are equivalent to the INSR auto-
phosphorylation sites Tyr1158, Tyr1162, and Tyr1163 (28). Together, the 
features of the LMTK3 kinase domain indicate that the critical residues 
required for its binding and hydrolysis of ATP are conserved (fig. S1).
Determination of the LMTK3 consensus  
phosphorylation motif and global analysis of the  
LMTK3-dependent phosphoproteome
Elucidating the preferred LMTK3 consensus phosphorylation motif 
is of critical importance to examine and identify in vitro LMTK3 
substrates and to decipher downstream pathways regulated by 
LMTK3 in vivo.
Following production of LMTK3cat (fig. S3A), we performed 
radiolabeled kinase assays using LMTK3cat to screen a PSPL 
consisting of 198 peptide mixtures as previously described (18). 
Quantification of the peptides’ signal intensities showed that 
LMTK3 appears to have a strong requirement for Arg residue at 
positions −3 and/or −2 (Fig. 2, A and B). Moreover, we observed a 
reduced phosphorylation on peptides with hydrophobic residues in 
the −3 through to the +1 position, indicating that these residues 
may be deterrents to LMTK3 substrate phosphorylation. On the ba-
sis of these data, we designed an optimal LMTK3 peptide substrate 
(LMTK3-tide: WRRFSFCMC) and generated mutant versions after 
substituting key residues at different positions. In vitro kinase 
assays further supported the importance of the −3, −2, and +1 
positions for maximal phosphorylation efficiency (Fig. 2C). Rab- 
coupling protein, recently described to be phosphorylated by LMTK3 
at Ser435 (29), contains a similar motif (R-R-S-S).
To confirm our results, we used a PepChip microarray slide 
carrying 192 peptides that contain experimentally verified phos-
phorylation sites for different kinases and performed an in vitro 
kinase assay with LMTK3cat. We observed variability in the phos-
phorylation of specific peptides containing analogous sequences to 
the one predicted from the PSPL assay [Arg residues predominantly 
at positions −3 and/or −2, as well as a Leu or Lys residue at posi-
tion −4 (L/K-R-R/X-X-S)] (fig. S3B). Among the newly identified 
substrates was HSP27 (also known as HSPB1), which we validated 
by kinase assays using full-length HSP27 (Fig. 2D and fig. S3C). We 
also pinpointed Ser15 and Ser82 as the main HSP27 residues phos-
phorylated by LMTK3 in vitro, using site-directed mutagenesis 
(fig. S3D), while both sites were in accordance with the identified 
LMTK3 phospho-motif.
There are many examples of kinase-dead (KD) mutants across 
various kinase families, which are typically based on disrupting res-
idues that assist ATP’s phosphates binding/catalytic transfer. The 
common approach (and one that is used to determine whether the 
target is a true kinase or a pseudo-kinase) is to mutate Lys72 (numbered 
after the first crystal structure of adenosine 3′,5′-monophosphate 
kinase with ATP bound), which will allow ATP to still bind but 
will not be able to catalyze phosphorylation. Single substitution 
of Lys72 by Ala is often sufficient to create a KD mutant; however, 
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and phosphate affinity. In LMTK3, these sites were identified as 
Lys193, Asp295, and Asp313 by using molecular modeling studies with 
ATP, as shown in fig. S3 (E and F). By mutating residues Lys193, 
Asp295, and Asp313 (fig. S3G), we demonstrated that the kinase is 
catalytically dead (from now on referred as LMTK3cat-KD) as shown 
by its inability to phosphorylate HSP27 in vitro (Fig. 2D).
To obtain information about the LMTK3-regulated global 
phosphoproteomic alterations, we performed SILAC experiments 
(30) in combination with phosphopeptide enrichment and liquid 
chromatography–tandem mass spectrometry (LC-MS/MS) analysis 
in MCF7 BC cells (Fig. 2E) and examined the effects of LMTK3 
overexpression. Of 4955 proteins that were identified in total and 
following normalization in respective total protein levels, we quan-
tified 4556 potential phosphopeptides that correspond to 1718 
proteins, as several proteins had more than one potential phospho-
rylation site. Among these phosphopeptides, 4022 phosphoserine, 515 
phosphothreonine, and 19 phosphotyrosine sites were character-
ized (table S2). Ultimately, we uncovered different phosphorylated 
proteins/amino acids that were either positively or negatively affected 
by LMTK3, suggesting a direct and/or indirect involvement of LMTK3 
Fig. 1. Crystal structure of LMTK3. (A) Structure of the kinase domain of LMTK3 showing the main features [Protein Data Bank (PDB) 6SEQ]. Blue, the glycine-rich loop; 
red, activation loop; salmon, the P+1 loop. The activation loop and the P+1 loop constitute the activation segment. Yellow, the catalytic loop; magenta, the kinase insert 
region. (B) Superimposition of the kinase domains of LMTK3 (green) and JAK1 (cyan). The activation loop of LMTK3 is shown in red and adopts an inactive conformation. 
The activation loop of JAK1 is shown in blue and adopts the active state. The two JAK1 phosphotyrosine residues (Tyr1034 and Tyr1035) are shown as yellow sticks. (C) Super-
imposition of LMTK3 and JAK1 active site (PDB 5KHW) residues involved in ADP binding. Key residues that bind ADP in JAK1 are positioned slightly differently to those of 
LMTK3 because of the different catalytic states of the kinases. However, residues in JAK1 that interact with ADP are conserved within LMTK3, although two noticeable 
differences are seen (LMTK3 Arg249 and Cys242 replaces Glu966 and Leu959), which are unlikely to affect ATP binding. (D) Superimposition of LMTK3 and EGFR active site 
(PDB 5CNO) residues involved in ATP binding. A comparison with the ATP-bound form of EGFR also shows strong conservation among residues of EGFR that bind ATP 
and amino acid residues at equivalent positions within LMTK3 and residues that are not conserved (Ala698, Met769, and Cys773 for Trp172, Cys242, and Asp246 in LMTK3), 
form main-chain interactions with bound ATP. [Green, amino acid residues of LMTK3 with black residue numbers; cyan, amino acid residues of JAK1 (top) or EGFR 
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during these posttranslational modifications (Fig. 2F). HSP27 was 
validated among the most significant hits, implying that it can also 
be an in vivo LMTK3 phospho-substrate. Most of the identified 
phospho-residues have been previously implicated in cancer, includ-
ing MLLT4 (Afadin)–Ser1799, PHIP (pleckstrin homology domain 
interacting protein)–Ser1315, ARHGEF11 (Rho guanine nucleotide 
exchange factor 11)–Thr1461/T1462, PLEKHF2 (pleckstrin homolo-
gy and FYVE domain containing 2)–Ser226, PDHA1 (pyruvate de-
hydrogenase E1  1 subunit)–Ser232, NUCKS1 (nuclear casein kinase 
and cyclin dependent kinase substrate 1)–Ser54, NASP (nuclear auto-
antigenic sperm protein)-Ser421, RBBP7 (RB binding protein 7, 
chromatin remodeling factor)–Ser3, STIP1 (stress induced phospho-
protein 1)–Ser16, and CSNK2A1 (casein kinase 21)–Ser287.
Together, we have determined the LMTK3 phosphorylation mo-
tif, characterized its phospho-dependent proteome in MCF7 cells, 
and identified HSP27 as a bona fide in vitro phosphorylation sub-
strate of LMTK3 to be taken forward and used in our biochemical 
assays and cell-based experiments described below.
High-throughput homogeneous time-resolved fluorescence 
screening identifies an ATP-competitive inhibitor  
targeting LMTK3
In parallel with the aforementioned structural and functional stud-
ies and considering the oncogenic role of LMTK3, we sought to 
identify and examine novel inhibitors for LMTK3 by implementing 
the experimental pipeline described in Fig. 3. Initially, we screened 
Fig. 2. Defining the LMTK3 consensus phosphorylation motif and identifying HSP27 as an LMTK3 substrate. (A) A spatially 198 components arrayed PSPL was 
subjected to in vitro phosphorylation with active LMTK3cat. A representative image of the average log2 values of two independent experiments is shown. (B) Scaled- 
sequence PhosphoLogo representation of the LMTK3 consensus phosphorylation motif. The size of the letter is proportional to the signal for the corresponding amino 
acid at the indicated position. (C) In vitro kinase assays using wild-type (WT) LMTK3cat as source of enzyme activity and peptide variants with individual amino acid 
substitutions at different positions. Data shown are the average of two separate experiments (±SEM). (D) Top: In vitro kinase assay using recombinant HSP27 as a substrate 
and WT LMTK3cat or kinase-dead (KD) LMTK3 mutant (LMTK3cat-KD) as source of enzyme activity. Bottom: Time course in vitro kinase assay using recombinant HSP27 
and LMTK3cat. (E) Schematic representation of SILAC proteomic experiment. Western blotting analysis of LMTK3 and FLAG-LMTK3 protein levels showing the transient 
overexpression of full-length pCMV6-LMTK3 (FLAG-tag) plasmid. m/z, mass/charge ratio. (F) Volcano scatter plot showing the log2 “normalized ratios” (H/L) against log10 
“intensity” (H+L) for each characterized phosphorylated protein (phosphopeptide) following overexpression of WT-LMTK3 in MCF7 cells. Proteins are displayed in cir-
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a library encompassing 28,716 compounds (Charles River Discovery 
Research Services UK Ltd.; formerly known as BioFocus DPI Ltd.), 
mainly enriched for ATP analogs, to detect substrate phosphoryla-
tion using a homogeneous time-resolved fluorescence (HTRF) 
assay as a readout (31). Approximately ~15% of the tested compounds 
displayed a >50% inhibition at 20 M concentration (Fig. 3A, phase 
1). We then narrowed down our hits to n = 160 based on their 
potency, physicochemical, and structural properties and performed 
a 10-point concentration-response profiling that gave a favorable 
range of median inhibitory concentration (IC50) values (24 nM to 
16 M) (Fig. 3A). Eventually, 38 of the 160 most active compounds 
(IC50, 24 nM to 2.6 M; table S3, A and B) were selected for our 
follow-up in vitro and cell-based efficacy studies.
Dose-dependent in vitro 32P -ATP radiolabeled kinase assays 
revealed variability of the inhibitory effects of the tested compounds 
with some of them demonstrating higher efficiency at low concen-
trations (<1 M) as measured by the phosphorylation of HSP27 by 
LMTK3 (Fig. 3B, phase 2 and fig. S4). We then used the interleukin- 
3 (IL-3)–dependent murine bone marrow–derived cell line FDCP1 
(32) and engineered an LMTK3-transformed clone (FDCP1-LMTK3) 
that relies on the constitutive expression of catalytically active 
LMTK3 for its survival and proliferation (fig. S5). Using this cell-
based approach, resembling the BA/F3 model that is extensively 
used in kinase research and drug discovery (33), we assessed the 
functional responses and potency of the selected inhibitors and 
determined their median effective concentration (EC50) values by 
monitoring the viability of FDCP1-parental and FDCP1-LMTK3 
cell lines (Fig. 3C, phase 3).
Taking into consideration all the results summarized in Fig. 3D 
and considering the novelty and physicochemical properties/
similarities of the top hit compounds, we focused on compound 
C28 (Fig. 3E and table S3B). We then assessed the ability of C28 to 
bind to LMTK3 by monitoring the thermal denaturation of LMTK3 
and the LMTK3/C28 complex using differential scanning fluorime-
try (DSF) and circular dichroism (CD) spectroscopy. As shown in 
Fig. 3 (F and G), both methods revealed an increase of the thermal 
stability of LMTK3 in the presence of C28, characteristic of ligand 
binding. The increase in the Tm value of LMTK3 upon C28 binding 
was determined at 2.6°C using DSF (50.4° ➔ 53.0°C; P = 0.001) and 
3.1°C using CD (51.1° ➔ 54.2°C; P = 0.002). Only a single transition 
was observed in the thermal melting curves, and thermal unfolding 
was irreversible because of protein aggregation.
To investigate the mechanism of action of C28 (10 M), we ex-
amined the effect of increasing substrate concentrations of HSP27 
on the inhibitory activity of the compound in the presence of a con-
stant amount of ATP. Our results revealed that the inhibitor does 
not affect the Km value (0.239 M in the absence versus 0.249 M in 
the presence of C28) but results in a substantially lower Vmax 
[108.6 mol/min versus 41.44 mol/min in the presence of C28 
(Fig. 3H)]. The unchanged Km value with increasing concentrations 
of HSP27 indicates that the inhibition is substrate independent. 
We next examined the effect of increasing concentrations of ATP 
at a fixed substrate (HSP27) concentration (0.6 M). The data 
from the steady-state analysis were fitted to the Michaelis-Menten 
equation and as shown in Fig. 3I, in the presence of C28, we ob-
served a significant increase in the apparent Km value from 0.0053 
to 0.038 M, indicating that C28 is a competitive inhibitor.
In summary, we provide evidence of an ATP-competitive inhib-
itor against LMTK3, following the recent discovery of cyclic guanidine–
linked sulfonamides as potential LMTK3 inhibitors (34). Given 
the oncogenic potential of LMTK3, identification of C28 provides 
a means of pharmacological inhibition as a tool for further investi-
gating its functions, to establish a start point for development of 
LMTK3 inhibitors.
Selectivity profile of C28 inhibitor
To determine a more detailed profile of the selectivity of this inhib-
itor, we screened it against a series of 140 kinases by performing a 
radioactive filter binding assay (www.kinase-screen.mrc.ac.uk/
services/premier-screen). We identified only 18 of 140 kinases whose 
activity was reduced >50% in the presence of 1 M C28 (table S4A) 
of which only 4 [CLK (CDC-like kinase), 5 nM; DYRK1 (dual 
specificity tyrosine phosphorylation regulated kinase 1), 6 nM; 
HIPK2 (homeodomain interacting protein kinase 2), 48 nM; and 
IRAK4 (interleukin 1 receptor associated kinase 4), 41 nM] had 
similarly low IC50 values to that of LMTK3 (67 nM) (Fig. 4A).
Following, to further examine the specificity of C28, we used 
an active site–directed competition binding assay (DiscoverX 
KINOMEscan) and quantitatively measured the interactions 
between C28 and 403 purified human kinases (Fig. 4B and table 
S4B) (35). The S(35) selectivity index of C28 was 0.186, as measured 
by the percentage of the kinome inhibited below 35% of the control 
at this concentration [S(35) = (number of kinases with %Ctrl <35)/
(number of kinases tested)]. C28 inhibited by >90% the activity of 
only 33 of 403 kinases, most of which (20 of 33) were different iso-
forms of the same proteins, highlighting an overall low promiscuity 
of C28 (Fig. 4B). It is worth mentioning that despite the different 
principles of the two assays used to examine the selectivity of the 
inhibitor (active site–directed competition binding assay and radio-
active filter binding assay), there was considerable overlap of iden-
tified kinases targeted by C28 marked in yellow in Fig. 4 (A and B), 
further validating the accuracy of our results.
Treatment of different BC cell lines with increasing concentra-
tions of C28 resulted in time- and dose-dependent degradation of 
LMTK3 (Fig. 4C), which was further validated following treatment 
with cyclohexamide, as shown by the decrease in half-life of LMTK3 
in the presence of C28 (Fig. 4D).
We have previously reported that silencing of LMTK3 results in 
down-regulation of ER and indeed, treatment with C28 decreased 
protein levels of ER (Fig. 4C). Moreover, we also observed a reduction 
in the phosphorylation of HSP27 in BC cells following pharma-
cological (Fig. 4E) or genetic inhibition of LMTK3 (Fig. 4F), sug-
gesting that HSP27 is also an in vivo (apart from in vitro) substrate 
for LMTK3. In particular, treatment with C28 for 4 hours, during 
which the stability of LMTK3 remained unaffected, resulted in a cell 
line–dependent variable decrease of HSP27 phosphorylation (Ser15 
and/or Ser82), without altering the total protein levels of HSP27. A 
reduction of total HSP27 was noticed in MDA-MB-231 cells after 
48 hours of C28 treatment, suggesting subsequent or indirect effects 
of the inhibitor.
Last, we also examined the effects of C28 on CLK2, DYRK1, 
HIPK2, IRAK4, and TRKA (tropomyosin receptor kinase A) kinases 
(total levels and phospho-sites linked to their activities), which were 
identified as potential C28 targets from our selectivity screening. As 
shown in Fig. 4G, treatment of BC cell lines with 10 M C28 for 
different time points led to degradation of IRAK4 and HIPK2. The 
level of C28 selected for these assays is above that used in the in vitro 
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Fig. 3. Identification of C28 as a potent inhibitor against LMTK3. (A) Top: Experimental pipeline to identify LMTK3 inhibitors. Middle: HTRF data showing coverage of 
different inhibitors per active cluster. Green stars are the 868 compounds chosen for further confirmation, showing >50% mean inhibition (blue crosses are nonselected 
compounds). Selections were biased toward higher potency, sensible calculated physicochemical properties, and structural coverage within each cluster. Bottom: 
HTRF data showing the range of IC50 values and purity of the top 160 compounds. (B) The IC50 value for C28 against LMTK3cat was determined by in vitro kinase assays. 
(C) EC50 values for C28 in FDCP1 and FDCP1-LMTK3 cell lines. Error bars represent the means ± SD from three independent experiments. (D) Table summarizing the IC50 
and EC50 values of the top 38 compounds. (E) Chemical structure of C28. (F) Characteristic thermal denaturation curves of LMTK3 (black) and LMTK3/C28 complex (red) as 
monitored by DSF and (G) CD spectroscopy, indicating the increased protein thermodynamic stability upon ligand binding. Tm values from DSF were determined from 
the maximum in the first derivative of the fluorescence with respect to the temperature, or the midpoint in the transition region by fitting a Boltzmann sigmoidal to the 
CD data. Experiments were performed in triplicate. DMSO, dimethyl sulfoxide; OD, optical density; RFU, relative fluorescence units. (H) Kinetic analysis of HSP27 phosphorylation 
by LMTK3 in the absence or presence of C28. Kinetic parameters were determined from nonlinear regression fit of the initial reaction rates as a function of HSP27 concentration 
to the Michaelis-Menten equation using Prism 8. (I) Kinetic analysis as a function of ATP concentration for 0.6 M HSP27 substrate, in the absence or presence of C28. Kinetic 
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Fig. 4. Selectivity of C28 toward LMTK3. (A) Selectivity profile of C28 (1 M) against 140 kinases using radioactive filter binding assay. The data are displayed as percent 
activity remaining of assay duplicates with an SD. Only kinases with >50% decrease in their activity are shown. The relative IC50 values are also presented. (B) Treespot 
interaction map depicting the kinome phylogenetic grouping, with kinases interacting with C28 (5 M) represented as red circles. The larger the diameter of the circle, 
the higher the C28 binding affinity to the respective kinase. Kinases whose binding was inhibited by C28 to less than 10% of the control (DMSO) are shown. Lower numbers 
indicate most probable hits to bind to C28. Overlapping kinases identified in assays (radioactive filter binding and site-directed competition binding) are highlighted in 
yellow. (C) Western blots of LMTK3 and ER in BC cell lines treated with increasing concentrations of C28 at different time points. Mean densitometry values of three 
independent experiments were calculated using ImageJ. GADPH, glyceraldehyde 3-phosphate dehydrogenase. (D) Effects of C28 on LMTK3 protein half-life in MDA-
MB-231 cells. Cells were treated with CHX (cycloheximide) (100 g/ml) and 10 Μ C28 (or DMSO) for different time points. The relative LMTK3 protein levels (−/+ C28) 
were calculated and plotted against the time of treatment with CHX. (E) Western blots of total and phospho-HSP27 (normalized versus total) in MCF7, T47D, and MDA-
MB-231 cell lines treated with 10 Μ C28 for different time points. Mean densitometry values of three independent experiments are shown. (F) Western blots of total 
and phospho-HSP27 (normalized versus total) in BC cell lines treated with either control or LMTK3 small interfering RNAs (siRNAs) for 72 hours. Mean densitometry values 
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effects of ATP-competitive inhibitors of kinases (36). Previous 
studies suggest that mutant TRKA in human acute myeloid leu-
kemia cells has been shown to be an HSP90-dependent kinase, 
subject to proteasomal degradation following HSP90 inhibition 
(37). It has also been demonstrated that for DYRK1A, ATP-com-
petitive inhibitors antagonize interaction between the target ki-
nase and kinase-specific cochaperone CDC37 in living cells (38). 
Thus, the assumption is that DYRK1A, in this context, is HSP90 
dependent. Both IRAK4 and HIPK2 are subject to proteasomal deg-
radation, which is blocked by MG132 treatment, but while the inhi-
bition of HSP90 in macrophages resulted in the destabilization and 
degradation of IRAK-1 but not IRAK4 (39), it is as yet unclear 
whether HIPK2 is an HSP90 client protein. Despite the fact that 
these results are, in some cases, in contrast to what we have seen in 
this study, previous work has shown that wild-type (WT) BRAF 
is not HSP90 dependent (40), whereas the V600E mutant is (41). 
Hence, the exact specificity for HSP90 may be quite variable be-
tween different cell lines and may also depend on the stability of 
the protein in question within a particular cell line. In aggregate, 
we report the identification of a selective LMTK3 inhibitor, which 
appears to have a secondary selectivity toward IRAK4 and HIPK2.
LMTK3 is an HSP90-CDC37 client protein and C28 acts by 
promoting the proteasome-mediated degradation of LMTK3
ATP-competitive inhibitors of several different oncogenic protein 
kinases that depend on HSP90-CDC37 for their biological stability 
have been shown to promote their degradation by antagonizing the 
binding of the CDC37 recruitment factor to the ATP-binding site 
of the kinase (36). This deprives the kinases of access to the chap-
erone system and channels them into ubiquitylation and subse-
quent degradation.
It has been observed that a conserved HPNI motif within CDC37 
mimics the conserved HPNI motif in kinases (42). The motif is 
HPNV in LMTK3 and is considered conserved and thus suggests 
that CDC37 may be able to recognize LMTK3. To determine whether 
LMTK3 is an HSP90 client kinase, we examined the effects of two 
HSP90 inhibitors, NVP-AUY922 and geldanamycin, on the stability 
of LMTK3. The HSP90-dependent CDK4 kinase (43) and HSP70, 
which are down-regulated or up-regulated, respectively, in response 
to HSP90 inhibition (44), were used as controls. As shown in Fig. 5 
(A and B), increasing concentrations of the HSP90 inhibitors led to 
a reduction of endogenous LMTK3 protein levels and induction of 
HSP70, indicating that LMTK3 is an HSP90- dependent kinase. 
As expected, degradation of LMTK3 following NVP-AUY922 and 
geldanamycin treatment also resulted in the down-regulation of 
ER (Fig. 5, A and B).
Moreover, the ability of CDC37 cochaperone to antagonize ATP 
binding by protein kinase clients (36) was also confirmed using an 
in vitro kinase assay, where HSP27 phosphorylation by LMTK3 was 
inhibited in the presence of either C28 or CDC37 (Fig. 5C). LMTK3 
was able to phosphorylate CDC37 in vitro, suggesting a previously 
unidentified role for LMTK3 within the chaperone regulatory pathway.
We then analyzed the effects of C28 on LMTK3 protein turnover 
following cotreatment with the proteasomal inhibitor MG132 and 
observed that LMTK3 was depleted from the detergent-soluble cell 
lysate fraction but accumulated in the insoluble fraction (Fig. 5D) 
indicative of a proteasomal mediated degradation, as a consequence 
of chaperone deprivation by C28. To rule out the possibility that the 
proteasome degradation of LMTK3, in response to C28 treatment, 
is not due to HSP90 inhibition, we tested the binding of C28 to 
HSP90 by isothermal titration calorimetry. Our results revealed 
that C28 does not bind to HSP90 (Fig. 5E). Furthermore, treatment 
of different BC cell lines with C28 had no effect on the protein 
levels of neither HSP90 nor CDC37 (Fig. 5F), further supporting 
that C28 is a specific LMTK3 inhibitor.
Following, to investigate the potential interaction between LMTK3 
and the HSP90 cochaperone CDC37, microscale thermophoresis 
(MST) was used. The insect cell–expressed LMTK3cat was cova-
lently labeled with a red NHS-647 fluorophore to allow monitoring 
of protein migration down an induced temperature gradient. Data 
quality in all experiments was determined by monitoring the fluo-
rescence intensity (fig. S6) and raw MST data (fig. S6) throughout. 
With the exception of the highest CDC37 concentration used (10 M), 
which was subsequently removed from the dataset, no consistent 
protein adsorption or aggregation was observed. As shown in Fig. 5G, 
titration of increasing concentrations of human CDC37 protein re-
sulted in a dose-dependent shift in the migration of NT647-LMTK3cat, 
demonstrating a direct interaction between the proteins (KD = 1.29 ± 
3.9 nM). On addition of C28 (20 M), the affinity of CDC37 for 
LMTK3 was considerably decreased (KD = 2.21 ± 1.17 M), demon-
strating a competitive binding mechanism. Last, the endogenous 
association of LMTK3 with the CDC37/HSP90 complex was also 
confirmed in MCF7 cells following immunoprecipitation with anti- 
LMTK3 antibody (Fig. 5H, left) and anti-CDC37 antibody (Fig. 5H, 
right), while treatment with C28 abolished this interaction (Fig. 5H, 
both panels). Furthermore, as shown in the right panel of Fig. 5H, C28 
did not affect the association between HSP90 and CDC37.
Together, these data demonstrate that LMTK3 is an HSP90-
CDC37 client protein and suggest that the mechanism of action of 
C28 on LMTK3 is mediated via blocking the direct interaction be-
tween LMTK3 with CDC37 and therefore preventing access to the 
molecular chaperone HSP90, resulting in LMTK3 degradation.
C28 exhibits potent anticancer activity in different human 
cancer cell lines
We then investigated the potential use of C28 as an anticancer strat-
egy by examining the viability of various BC cell lines (and one non-
transformed breast cell line; MCF12A) in the presence of increasing 
concentrations of C28. As shown in Fig. 6A, C28 was able to inhibit 
the growth of BC cells with IC50 values ranging from 6.5 to 8.64 M, 
while the noncancerous cell line (MCF12A) appeared to be less 
sensitive to C28 (IC50, 14.77 M).
We next submitted C28 to the DTP of the NCI and screened it 
against a panel of 60 human cancer cell lines (https://dtp.cancer.gov/
discovery_development/nci-60/). At a 10 M dose, C28 inhibited 
all cancer cell lines by >50% (Fig. 6B). Considering the significant 
growth inhibition demonstrated, the NCI decided to further evalu-
ate C28 at five doses. The results revealed that most of the leukemia, 
melanoma, ovarian, and central nervous system cell lines were 
more resistant to C28, while renal cancer cells appeared to be more 
sensitive (table S5). These data demonstrate possible anticancer 
applicability of C28 in different tumor types.
Considering that our previous (5) and current genetic studies 
(Fig. 6C) have revealed an increased rate of apoptosis of BC cells 
following LMTK3 inhibition [small interfering RNA (siRNA)], we 
assessed the effects of C28 using annexin V and 7-AAD (7-amino-
actinomycin D) staining. As anticipated, C28 treatment triggered 
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Fig. 5. C28 promotes proteasome-mediated degradation of LMTK3, an HSP90 client protein. (A) Western blots of LMTK3, HSP70, and CDK4 in BC cell lines 
following treatment with increasing concentrations of NVP-AUY922 for 72 hours. (B) Western blots of LMTK3, HSP70, and CDK4 in BC cell lines following treatment with 
increasing concentrations of geldanamycin for 72 hours. (C) In vitro kinase assays using recombinant HSP27 as a substrate and LMTK3cat as source of enzyme activity, 
examining the effects of C28 treatment or CDC37 addition. (D) Western blots of cell lysates from BC cell lines incubated with 10 M of MG132 for 4 hours before treatment 
with C28 (10 M) for the indicated time points. LMTK3 protein levels in the detergent-soluble and detergent-insoluble fractions are presented. (E) Isothermal titration 
calorimetry examining the ability of C28 to bind HSP90. Injection of 0.2 mM C28 into 20 M human HSP90 showed no detectible heat of interaction. (F) Western blots 
of LMTK3, HSP90, HSP70, and CCD37 in BC cell lines following treatment with increasing concentrations of C28 for 48 hours. (G) Normalized dose-response curves com-
paring thermophoresis of NT647-LMTK3cat on titration of increasing concentrations of CDC37 in the presence (red, KD = 2.21 ± 1.17 M) or absence (blue, KD = 1.29 ± 3.9 nM) 
of 20 M C28. Error bars represent SE, n = 5. KD values were calculated from fitted data. (H) Left: LMTK3 was immunoprecipitated (IP) from MCF7 cells stably overexpressing 
LMTK3, in the presence (48 hours) or absence of C28 and the complexes were immunoblotted for LMTK3, CDC37, and HSP90. Right: CDC37 was immunoprecipitated from 
MCF7 cells stably overexpressing LMTK3, in the presence (48 hours) or absence of C28, and the complexes were immunoblotted for CDC37, LMTK3, and HSP90. Western 
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Fig. 6. C28 impairs the viability of various human cancer cell lines. (A) Left: Viability of nontransformed and BC cell lines treated with increasing concentrations of C28 
for 72 hours. The IC50 values are means from three independent experiments. Right: Western blots of LMTK3 in nontransformed and BC cell lines. (B) One-dose screening 
of C28 (10 M; 24 hours) on the NCI-60 panel of tumor cell lines. The percent growth of C28-treated cells is shown. Negative values represent lethality. NSCLC, non-small 
cell lung cancer. (C) Western blots of BCL-XL, BCL2 and cleaved poly(ADP-ribose) polymerase (PARP) in BC cell lines following siRNA silencing of LMTK3 for 72 hours. 
GADPH was used as a loading control. (D) MCF7, T47D, MDA-MB-231, and MCF12A cell lines were treated with increasing concentrations of C28 for 72 hours, and the 
percentages of apoptotic and dead cells were analyzed by annexin V and 7-AAD staining. Results are expressed as means ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001. Each experiment was conducted at least three times. (E) Western blots of LMTK3, BCL2, and BCL-XL and cleaved PARP in MCF7, T47D, MDA-MB-231, and 
MCF12A cell lines treated with increasing concentrations of C28 for 72 hours. GADPH was used as a loading control. (F) Western blots of BCL2 and cleaved PARP levels in 
T47D and MDA-MB-231 cell lines treated with 10 M C28 for 72 hours followed by LMTK3 overexpression for 48 hours. Tubulin was used as a loading control. Mean densitome-
try values of three independent experiments are shown. (G) T47D and MDA-MB-231 cell lines were treated with 10 M C28 for 72 hours, followed by LMTK3 overexpression 
for 48 hours, and the percentages of apoptotic and dead cells were analyzed by annexin V and 7-AAD staining. Results are expressed as means ± SEM. Each experiment 
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cellular senescence. The nontransformed MCF12A breast cell line 
showed a low percentage of cell death even at high concentra-
tions of C28 and longer time points, suggesting that nontrans-
formed breast epithelial cells may evade death while working on 
recuperating from C28 treatment (Fig.  6D). Western blotting 
demonstrated a degradation of LMTK3 levels in MCF12A but no 
dependence, in agreement with the cell viability/apoptosis results 
(Fig. 6E). As expected and consistent with a cell death apoptotic 
mechanism, we also observed a decrease in Bcl-xL (B-cell lymphoma- 
extra large) and Bcl-2 (B-cell lymphoma 2) antiapoptotic proteins 
and an increase in cleaved poly(ADP-ribose) polymerase (PARP) 
in the BC cell lines (Fig. 6E). Together, these data suggest that 
C28 predominantly displays its effects against cancer cells, results 
that require clinical exploration.
To further confirm the specificity of C28 against LMTK3 and 
demonstrate that the observed apoptotic effects are due to a great 
extent via the C28-mediated LMTK3 inhibition, we performed gain- 
of-function experiments overexpressing full-length LMTK3 follow-
ing C28 treatment, since LMTK3 overexpression concomitant with 
drug exposure did not outcompete the effects of the drug. As shown 
in Fig. 6F, recovery of LMTK3 levels led to an increase of BCL2 and a 
decrease in cleaved PARP levels, in accordance with the antiapoptotic 
role of LMTK3, followed by an overall decrease of cell death within 
the short time boundaries of the experimental setup (Fig. 6G). Be-
cause of the fact that LMTK3 is ubiquitously expressed in cancer 
cell lines (12), it was not possible to further test the specificity of 
C28 in an LMTK3-null cell line model. Attempts to generate LMTK3 
knockout BC cell lines using CRISPR-CAS9 were also unsuccessful, 
as all LMTK3-KO clones were nonviable, in line with previous 
reports (13).
As an extra proof-of-concept study, we looked into the potential 
additive effect of C28 following siRNA silencing of LMTK3. As 
anticipated, either genetic or pharmacological inhibition of LMTK3 
led to an increase in apoptosis (fig. S7, A and B) and a decrease in 
cell viability (fig. S7C). When combined with siLMTK3, C28 treat-
ment had an additive effect in the observed phenotypes and a simul-
taneous reduction of the residual LMTK3 protein levels. Together, 
these data suggest that C28 confers its anticancer functions to a 
great extent via LMTK3-mediated signaling, without ruling out the 
possibility of any off-target effects, which are invariably common 
with any small-molecule ATP inhibitors (45).
C28 inhibits tumor growth in orthotopic and transgenic 
mouse models of BC
Before testing the use of C28 in mouse models, its solubility was 
assessed in various formulation vehicles and dissolution conditions. 
We also investigated the pharmacokinetic (PK) properties of C28 in 
nude Balb/c mice at different doses following intravenous, intraper-
itoneal, and oral administration. Analysis of plasma samples by 
LC-MS/MS revealed that C28 (5 mg/kg), dosed intravenously, had 
a peak concentration (Cmax) of 1533 ng/ml (4.3 M) at 5 min after 
injection, which was countered by a short half-life (T1/2 ~ 10 min), 
whereas lowering the dose to 1 mg/kg led to very little exposure 
(Cmax = 185 ng/ml). The optimal route of administration appeared 
to be intraperitoneally at 10 mg/kg, where Cmax was 839 ng/ml with 
a T1/2 of ~59 min or orally (Cmax = 632 ng/ml; T1/2 ~ 62 min) (Fig. 7A).
As we showed oral bioavailability of C28, we evaluated its antitumor 
activity in the MMTV (mouse mammary tumor virus)-Neu mammary 
tumor model transgenic model in which a constitutively active mouse 
Neu protein is expressed under control of the mouse mammary tumor 
virus promoter. Once tumors became palpable, mice were treated 
orally daily, with either vehicle control [5% dextrose/PEG400 
(polyethylene glycol 400) in a 1:1 ratio] or C28 at a final concentra-
tion of 10 mg/kg (table S6A). As shown in Fig. 7B, C28 nearly com-
pletely abrogated tumor growth compared to the vehicle-treated 
group. Histopathologic analysis of tumor sections and other organs 
(lung, stomach, heart, kidney, liver, and spleen) between different 
groups did not show any notable differences, further demonstrat-
ing the lack of toxicity of the C28 inhibitor (Fig. 7C and fig. S8). 
Moreover, Ki-67 IHC analysis showed decreased proliferation fol-
lowing treatment with C28 (Fig. 7D). Regarding LMTK3, IHC stain-
ing revealed a reduction of LMTK3 expression in the C28-treated 
tumors, albeit a degree of variability was observed in certain cases 
(Fig. 7E). The IHC data here confirm ex vivo our on- target pertur-
bation assays.
Next, the antitumor activity of the LMTK3 inhibitor was also 
evaluated using a BC xenograft mouse model where TNBC MDA-
MB-231 cells were injected subcutaneously into immunocompromised 
mice. Once tumors were palpable, mice were divided into different 
groups and were treated orally daily at either control vehicle or C28 
with a final concentration of 10 mg/kg (table S6B). After 23 days, 
treatment with C28 significantly impeded growth compared to the 
control group (Fig. 7F), with no changes in body weight observed 
(vehicle group: day 0, 21.22 g ➔ day 15, 21.42 g versus C28-group 
day 0, 21.77 g ➔ day 15, 21.84 g). Similar results were obtained 
in a separate study using luciferase-labeled MDA-MB-231 and 
treatment with C28 (either 10 or 30 mg/kg) (Fig. 7G and table S6C). 
In aggregate, our data demonstrate potent preclinical anticancer 
activity of C28 in vitro and a delay of tumor onset in vivo in 
mice models.
DISCUSSION
LMTK3 has been reported to be involved in several cancer types 
(5, 7, 11, 14–16). However, the lack of crystal structure has impeded 
an understanding of the role of this protein and its interactions with 
other molecules. By solving the crystal structure of inactive LMTK3, 
we showed that it has all the hallmarks (key features and residues) 
of an active protein kinase, able to be activated, to bind and hydro-
lyze ATP (Fig. 1 and figs. S1 and S2). In particular, the K/E/D/D 
signature motif plays important structural and catalytic roles and 
comprises residues Lys193 in the 3 strand, Glu210 in the center of 
the C helix, Asp295 of the catalytic loop, and Asp313, the first resi-
due of the activation segment. Although our crystallization exper-
iments stabilized LMTK3 in an inactive conformation, which is 
common in such studies (46), we could clearly detect the catalytic 
activity of LMTK3 in our biochemical assays. This suggests that the 
insect cell protein production protocol used herein may yield a low 
amount (yet considerable for experimental purposes) of catalytically 
active protein (either phosphorylated or in an active conformation, 
but lacking phosphorylation) within the overall preparation, which 
could also explain the requirement of relatively high concentrations 
of LMTK3 in our in vitro kinase assays. The enzymatic activity of 
LMTK3 was validated following mutations at key residues Lys193, 
Asp295, and Asp313, which rendered the kinase inactive. In LMTK3, 
the activation segment DFG motif is instead DYG (residues 313 to 
315). Although a DYG motif is not common, it has been reported in 
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Fig. 7. C28 impedes tumor growth of BC mouse models. (A) PK parameters of C28 following a single intravenous (IV), intraperitoneal (IP), or oral (PO) dose administra-
tion in male BALB/c mice (n = 4 per time point). *, based on 1 mg/kg intravenous group. **, based on 5 mg/kg intravenous group. Intravenous dose of 5 mg/kg was lethal 
for some mice, and therefore, the dose was decreased to 1 mg/kg. (B) Tumor growth in vehicle- and C28-treated groups (n = 6 each) of MMTV-Neu transgenic mice. Un-
paired t test was performed using Prism 8. Results are expressed as means ± SEM; *P < 0.05. (C) Representative images of hematoxylin and eosin (H&E) staining of tumor 
sections from MMTV-Neu animals treated with vehicle or C28 (10 mg/kg). Original magnification, ×10. Scale bar, 100 m. (D) Representative IHC images of Ki-67 expres-
sion in tumor sections from MMTV-Neu animals treated with vehicle or C28 (10 mg/kg). Original magnification, ×40. Scale bar, 50 m. The percentage of Ki-67–positive 
cells versus the total number of cells is shown. Data represent the average of four vehicle and five C28-treated samples. Results are expressed as means ± SEM; ***P < 
0.001. (E) Representative IHC of LMTK3 expression in tumor sections from MMTV-Neu animals treated with vehicle or C28 (10 mg/kg). Original magnification, ×20. Scale 
bar, 100 m. (F) Tumor growth in vehicle- and C28-treated groups (n = 14 each) of MDA-MB-231 mice xenografts. (G) Box-and-whisker plots comparing vehicle (n = 6)–
treated and C28-treated (10 mg/kg, n = 6 and 30 mg/kg, n = 5) groups of MDA-MB-231–luciferase mice xenografts groups at day 21. Unpaired t test was performed using 
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kinase C (48). In the inactive “D313-out” state, Tyr314 is in an “in” 
conformation pointing past the gatekeeper residue Met239 and oc-
cupies regions of space that would overlap with the adenine ring of 
bound ATP (fig. S3). Design of kinase inhibitors that targets the 
inactive “DFG-out” conformation (type II inhibitors) offers poten-
tial of higher selectivity as compared to type I kinase inhibitors that 
target the active state, in addition to a profound impact on cellular 
activity (49). However, until now, the structure of half of all protein 
kinases in the human kinome has been resolved. From a total of 
5200 structures of catalytic domains of human and mouse protein 
kinases contained in the KLIFS database, 84.5% (4393 structures) 
represent an active, DFG-in state, whereas the remaining 15.5% are 
annotated as inactive, DFG-out and atypical, DFG-out conforma-
tions (50). Nonetheless, efforts are under way to obtain a crystal 
structure of LMTK3 in the active state and to identify kinases that 
may phosphorylate tyrosine residues within the activation loop of 
LMTK3 [Tyr321, Tyr325, and Tyr326, which correspond to the auto-
phosphorylation residues Tyr1158, Tyr1162, and Tyr1163 of INSR 
kinase (fig. S1)]. Overall, our optimized protein production protocol 
and the structure of LMTK3 presented herein will enable a supply 
of protein for further structural and functional studies and facilitate 
the structure-based design of inhibitors.
Considering the mounting role and involvement of LMTK3 in 
different malignancies and cellular processes (5–14), we attempted 
to uncover the LMTK3 consensus phosphorylation motif, another 
milestone of this study, and to identify potential in vitro and/or 
in vivo LMTK3 substrates. Radiolabeled assays using a PSPL com-
prising diverse peptide mixtures revealed a consensus sequence with 
a strict requirement for R residues at positions −3 and/or −2 (Fig. 2, 
A to C). Since LMTK3 is predicted in silico to have dual phospho- 
specificity [serine/threonine (S/T) and Y], a similar approach using 
a Y residue as a phosphoacceptor site would add more knowledge 
to this topic. Moreover, bearing in mind the documented and, in 
some cases, analogous roles of the other two isoforms (LMTK1 
and LMTK2) in different diseases, it would be interesting to ex-
amine and compare the substrate specificities among all family 
members. Through the PSPL approach and other biochemical as-
says, we also identified HSP27 as a bona fide in vitro phosphoryl-
ation substrate for LMTK3 that can serve as a useful readout tool 
(Fig. 2D and fig. S4).
In parallel, using SILAC-based quantitative proteomics, we 
described the LMTK3-dependent global phosphoproteomic pro-
file in BC cells (MCF7) and identified a large number of phos-
phoryl ated proteins that were significantly modulated by LMTK3 
(Fig. 2, E and F). As anticipated, we detected certain hits closely 
matching the predicted LMTK3 consensus motif that have been 
previously reported to be implicated in different BC subtypes in-
cluding BAD-S118, PRKD2-S197, RPRD2-1099, ALKBH5-S361, 
HSP90AB1-S452, and DDX17-S599. Additional identified phos-
phosites, which did not match the LMTK3 phosphorylation motif, 
either may represent indirect LMTK3-modulated targets or could 
still be direct substrates that do not fall under the canonical LMTK3 
sequence as is the case for multiple kinases. Ultimately, use of a KD 
mutant LMTK3 construct would allow us to further establish the 
kinase-dependent (direct) phosphorylated targets of LMTK3. This 
is part of our ongoing studies. Following, to gain further insights 
into the global signatures of the identified LMTK3-dependent 
phosphorylation events, we performed Funrich analysis (www.
funrich.org/) of the molecular functions, cellular components, 
biological processes, and pathways to which the uncovered phos-
phorylated proteins belong. A notable enrichment in molecular 
function terms related to transcription regulator activity, protein 
S/T kinase activity, and RNA and cytoskeletal protein binding 
was unveiled. Moreover, a similar distribution between cytoplasmic 
and nuclear cell components was observed, as anticipated, con-
sidering the universal subcellular distribution of LMTK3. Last, bio-
informatics analysis of the signaling pathways and the functional 
protein- protein interaction networks affected by LMTK3 revealed a 
large number and a variety of connections further supporting the 
diverse and multiplex role of LMTK3 in signal transduction. Thus, 
the phosphorylation state of these proteins could be directly and/or 
indirectly modulated by LMTK3. Ultimately, the robust and com-
prehensive information derived from these distinct but comple-
mentary approaches (PSPL and phospho-proteomics) will assist us 
in deciphering and elucidating the pathways that LMTK3 is impli-
cated in and help us map LMTK3 on the atlas of cancer signaling 
networks.
Alongside our structural studies, we adopted a high-throughput 
screening approach to identify compounds that could be promising 
candidates for drug development against LMTK3. To achieve this, 
we analyzed 28,716 small-molecule inhibitors using a wide range of 
biochemical, biophysical, and cell-based assays (Fig. 3). Herein, we 
report the first tool compound, namely C28, which binds to and 
inhibits LMTK3 (ATP-competitive inhibitor) with high selectivity 
and demonstrates effective anticancer effects in a variety of cancer 
cell lines and in in vivo BC mouse models, apparently sparing 
the normal epithelium. Cocrystallization of LMTK3 with C28 or 
AMPPNP has thus far not been possible, partly because of the 
considerably reduced yield of constitutively active LMTK3 protein 
in our insect cell expression system. Failure to cocrystalize with C28 
suggests that perhaps it does not bind the inactive LMTK3 state that 
we crystalized and that it might instead target an active state confor-
mation of the kinase. Thus, the difficulties regarding the cocrystal-
lization studies are related to the fact that a great proportion of the 
protein appears to occupy a stable inactive conformation, which 
appears to be the preferential state for crystallization under the con-
ditions tested to date. However, ongoing attempts to resolve these 
issues by stabilizing the expressed protein, or expressing activated 
LMTK3 protein, will in time provide sufficient material for com-
plete screening and optimization of crystallization conditions.
Through a range of techniques, we have validated that LMTK3 
has the classic characteristics of an HSP90 client protein. HSP90 is a 
well-characterized molecular chaperone that plays an essential role 
in the folding and stability of a host of cellular proteins, notably 
including a large subset of eukaryotic protein kinases (51, 52). Re-
cruitment of client kinases is mediated by the HSP90 cochaperone 
protein CDC37/p50, which directly interacts with both the HSP90 
dimer and the client kinase, bridging formation of a tetrameric 
complex (42, 53). In recent years, studies into the CDC37-mediated 
recruitment of kinases to the HSP90 system have demonstrated that 
the CDC37-kinase interaction is antagonized by ATP-competitive 
kinase inhibitors (36). From these data, we propose that C28 not 
only competes with ATP binding to the kinase active site but also acts 
to promote LMTK3 degradation through a mechanism of chaperone 
deprivation (Fig. 7H), as it has been previously shown for other 
kinases and their selective inhibitors (36). Inhibition of the CDC37 
interaction deprives LMTK3 of access to the HSP90 chaperone 
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Future work will be required to identify the E3 ubiquitin ligase(s) 
involved in this process.
CDC37 phosphorylation by LMTK3 provides an additional 
insight into LMTK3 function. Phosphorylation of CDC37 is a key 
mechanism for regulating client kinase access to the HSP90 chaper-
one system. In particular, phosphorylation by CK2 (54) and YES 
kinases (55), notably both Hsp90 client proteins have been well 
documented as critical modifications required for normal function. 
Additional work will be necessary to fully determine the impor-
tance of LMTK3-mediated CDC37 phosphorylation on the chaper-
one system as a whole.
The ability of C28 to abolish both the catalytic and the scaffold-
ing functions of LMTK3 has allowed us to identify both LMTK3 
phospho-substrates as well as interacting partners that depend on 
LMTK3’s scaffolding properties. Our ongoing medicinal chemistry 
strategy, using structure-activity relationship data, focuses on the 
optimization of potent and selective LMTK3 inhibitors with low 
off-target effects and suitable physicochemical properties that could 
preferentially block the LMTK3 kinase activity. Achieving this goal 
will result in the identification of kinase-dependent LMTK3 sub-
strates, which will assist in further deciphering the role of LMTK3 in 
signal transduction.
Moreover, C28 had no toxicity in normal tissues (fig. S8) or body 
weights (tables S10 and S11) in BC mouse models, while its anti-
proliferative and proapoptotic effects on a nontransformed breast 
cell line (MCF12A) were significantly lower compared to other BC 
cell lines. Additional testing in other types of noncancerous cell 
lines will provide further validation of these findings. Given the 
short half-life of the drug, in vivo oral dosing at 10 mg/kg signifies 
that exposure levels above the IC50 and less so, above the IC90 of the 
drug, would be attainable for only a few hours.
In aggregate, the development of oral LMTK3 inhibitors may 
have the potential for broad clinical use, either as monotherapy or 
as a combinational therapy, [i.e., combined, for example, with aro-
matase inhibitors in ER+ BC in the same way the CDK4/6 inhibitors 
are (56, 57) and combined with the standard-of-care chemotherapy 
in triple-negative models]. More precisely, in the case of TNBC, de-
spite immunotherapies being helpful at one level (58), there are no 
approved targeted therapies. A recent report also showed promising 
results regarding the use of CDK12/CDK13 inhibitors alone or in 
combination with the chemotherapeutic agent cisplatin (59). There-
fore, on the basis of aberrant expression of LMTK3 in TNBC and 
work showing that genomic inhibition of LMTK3 leads to inhibi-
tion of cell proliferation, invasion, and migration (10, 12, 13), an 
LMTK3 inhibitor could represent an attractive candidate for clinical 
trials. On the other hand, since the mechanism of endocrine and 
chemotherapy resistance in BC still remains largely unexplained, 
there remains a need to treat these patients in a more focused way, 
for example, in the setting of progression on CDK4/6 inhibitors. On 
the basis of our results so far (in vitro, in vivo, and clinical data from 
patient specimen cohorts), inhibition of LMTK3 may be important 
in tamoxifen (Tam) (5, 8, 9) and doxorubicin (Dox) resensitization 
(10). Consequently, an LMTK3 inhibitor could be used alongside 
established therapies (e.g., Tam and Dox) to increase the sensitivity 
of tumors and/or potentially overcome resistance. Last, the subse-
quent down-regulation of ER protein levels following LMTK3 
inhibition suggests additional opportunities to use LMTK3 inhibi-
tors in patients with ESR1 mutations and/or in ESR1 fusions that 
may be currently untargetable (60).
MATERIALS AND METHODS
LMTK3 protein expression and purification
The WT catalytic domain of LMTK3 (LMTK3cat; amino acids 134 to 
444) was cloned into pOPINEneo, which confers a C-terminal 8× 
His tag, using InFusion technology. This plasmid was cotransfected 
into Spodoptera frugiperda (Sf9) cells with linearized Autographa 
californica baculovirus bacmid using FuGENE HD (Promega, no. 
E2311). Briefly, 0.5 ml of Sf9 insect cells was plated in a 24-well plate 
at 5 × 105 cells/ml and allowed to attach. A transfection cocktail was 
then made by mixing 2.5 l of linearized bacmid with 100 to 500 ng 
of plasmid DNA in 50 l of SF900III medium (Thermo Fisher 
Scientific, no. 12658001). To this, 1.5 l of FuGENE HD was added 
and mixed, and the cocktail was incubated at room temperature for 
30 min. The transfection cocktail was then added to the attached Sf9 
cells in the 24-well plate. The plate was incubated at 27°C for 7 days 
before harvesting the supernatant that contained the P0 virus. This 
virus was amplified by infecting 50 ml of cells in suspension at 1 × 
106 cells/ml with 100 l of virus. Cells were incubated at 27°C for 
7 days with shaking at 120 rpm. The P1 virus was harvested and 
filter-sterilized before use. Sf9 cells (2.5 liters) at 1 × 106 cells/ml were 
infected with 2.5 ml of P1 virus and incubated for 3 days at 27°C 
with shaking at 120 rpm. The cells were harvested by centrifugation 
and frozen before purification.
The pellet from 2.5 liters of Sf9 culture was defrosted and resus-
pended in ~100 ml lysis buffer [50 mM tris (pH 7.5), 500 mM NaCl, 
30 mM imidazole, and 0.2% Tween 20] containing 5 l Benzonase 
nuclease (250 U/l; Sigma-Aldrich, no. 9025-65-4) and a 50 l pro-
tease inhibitor cocktail (Sigma-Aldrich, no. P8849). Cells were bro-
ken by passing through a Basic Z cell disruptor at 241.32 N/mm2 
before removal of the cell debris by centrifugation at 30,000g for 
30 min at 4°C. After clarification, the cell lysate was filtered through 
a 0.2-m filter before being applied to a 1-ml HisTrap FF column 
(GE Healthcare, no. 11-0004-58). After washing with 50 mM tris 
(pH 7.5), 500 mM NaCl, and 30 mM imidazole, the protein was 
eluted in 50 mM tris (pH 7.5), 500 mM NaCl, and 500 mM imidazole 
before being automatically applied to a HiLoad 16/60 Superdex 
200 column (GE Healthcare, no. 8-9893-35) equilibrated in 20 mM tris 
(pH 7.5) and 200 mM NaCl. All purification steps took place at 4°C. 
Fractions containing the WT LMTK3 kinase domain (LMTK3cat) 
were analyzed by SDS–polyacrylamide gel electrophoresis (SDS-
PAGE) before being combined and concentrated. On average, 1 mg 
of purified protein (>95% pure by SDS-PAGE) could be obtained 
per liter of infected Sf9 cells. The identity of the protein was con-
firmed by intact protein mass spectrometry (measured mass = 
36806.44 Da; expected mass with 1× acetylation = 36805.13 Da). 
Similar protocol was used for generating green fluorescent protein 
(negative control) and as the mutant (KD; LMTK3cat-KD) recom-
binant LMTK3 protein (amino acids 134 to 444), which included 
the following mutations K193A, D295A, and D313A.
Crystallization, data collection, and processing
The WT catalytic domain of LMTK3 (LMTK3cat; amino acids 134 
to 444) was concentrated to 3.2 mg/ml in 20 mM tris (pH 7.5) con-
taining 200 mM NaCl and crystallized at 4°C from various optimi-
zations of Molecular Dimensions PACT screen well F10 [100 mM 
bis-tris propane (pH 6.5), 20% (w/v) PEG3350 and 20 mM sodium/
potassium phosphate]. Optimizations included simple dilution of the 
original condition and change of pH according to the method of Walter 
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Optimized crystals were grown in 70 mM bis-tris propane (pH 6.5), 
14% (w/v) PEG-3350, 14 mM sodium/potassium phosphate, and 
30% (w/v) sucrose at 4°C using the sitting drop method by mixing 
protein and reservoir in a 1:1 ratio. Diffraction data were collected 
at beamline I24, Diamond Light Source with an x-ray wavelength 
of 0.9686 Å and recorded using a Pilatus3 6M detector. Data were 
merged from four crystals to obtain a final dataset. Diffraction data 
were integrated using XDS (62) and scaled using AIMLESS (63). 
The structure was solved by molecular replacement using PHASER 
(64) using 1IRK as a search model. The structure was refined using 
Phenix (65) and BUSTER (66) and rebuilt between refinement 
cycles using Coot (67). Validation was performed using MolProbity 
(68), QCCheck, and tools within Coot and Phenix.
CDC37 protein expression and purification
BL21(DE3) cells were transformed with a pET27 vector expressing 
human CDC37 with a C-terminal 6× His tag. Transformed cells 
were grown in 3-liter LB media, and protein expression was induced 
with 0.5 mM isopropyl -d-1-thiogalactopyranoside. Protein was 
expressed at 20°C for 16 hours. Cells were resuspended in lysis buffer 
[20 mM tris (pH 8), 4°C, 100 mM NaCl, and 1 mM imidazole with 
protease inhibitors (Roche)] and lysed by sonication. Lysate was 
purified by IMAC with 60-ml Co2+ resin eluting in 500 mM imidazole. 
Eluted proteins were further purified by size exclusion chroma-
tography (SEC) using a Superdex 200 26/60 column (GE Healthcare) 
in SEC buffer [20 mM tris (pH 7.4), 4°C, 500 mM NaCl, 1 mM 
dithiothreitol (DTT), and 1 mM EDTA], followed by ion-exchange 
chromatography using Q Sepharose (GE Healthcare, 60 ml) by 
gradient elution to 1 M NaCl [20 mM tris (pH 7.4), 4°C, 1 mM 
DTT, and 1 mM EDTA]. Fractions were analyzed by SDS-PAGE and 
Coomassie staining. Purified protein was concentrated to 1.5 mM 
and snap-frozen for storage at −80°C.
PepChip analysis
PepChip microarray slides are spotted with a duplicate set of 192 
peptides that contain experimentally verified phosphorylation sites 
for different protein kinases and their original surrounding residues. 
Each peptide consists of eight to nine amino acids, of which approx-
imately the central position corresponds to the putative phosphoryl-
ation site (Ser, Thr, or Tyr residue). For incubation of the PepChip 
slide, an in vitro kinase assay was performed, using 2 g of WT 
LMTK3-KD mixed with 5 l of 32P -ATP. The mix was brought 
onto a cover slide, after which the PepChip was posed over the sam-
ple and turned around, following incubation for 4 hours at 30°C in 
a closed wet box to prevent drying of the slide. The cover slide was 
rinsed off the PepChip with 50 mM tris (pH 7.5), 150 mM NaCl, 
and 0.02% Tween 20 (TBST), and the PepChip was then washed 
twice with 2 M NaCl, once with 2 M urea, twice with 10% SDS, and 
three times with MilliQ water in a washing tube. The intensity of 
phosphorylated substrates was then quantified using standard 
autoradiography.
Arrayed PSPL
A PSPL screening was performed as previously described (AnaSpec, 
catalog no. AS-62017-1, UK) (18). Briefly, each peptide contained a 
centrally fixed phosphoacceptor residue (equimolar mixture of Ser/
Thr), while 1 of the 20 naturally occurring amino acids was fixed at 
one of the nine surrounding positions. The remaining positions in 
each peptide contained a degenerate, approximately equimolar, 
mixture of the 17 amino acids excluding cysteine (C), S, and T. 
Aliquots of each reaction were spotted onto a membrane and ex-
posed to a phosphor storage screen. Phosphate incorporation was 
quantified using ImageJ. Each value was then divided by the aver-
age phosphate incorporation for all amino acids at that position to 
yield a selectivity value for each amino acid at that position relative 
to the phosphoacceptor site. An optimal LMTK3 peptide substrate 
was designed, and mutant versions were generated with individual 
amino acid substitutions at different positions (JPT, Cambridge 
Bioscience Limited). Radiolabeled in vitro kinase assays were per-
formed following the manufacturer’s instructions (JPT, Cambridge 
Bioscience Limited).
In vitro kinase assays
32P -ATP in vitro kinase assays were performed in-house as we 
have previously described (69). The selectivity “premier screening” of 
C28 against a panel of 140 protein kinases was performed at the MRC 
International Centre for Kinase Profiling unit (www.kinase-screen.
mrc.ac.uk/services/premier-screen).
SILAC phosphoproteomic experiment
To define the LMTK3-regulated phosphoproteome profile, a quan-
titative mass spectrometry analysis using SILAC was performed. 
Briefly, MCF7 cells were cultured for seven cell divisions in either 
R0K0 “light” medium (Primacyt, no. DMEM-14-LM014), contain-
ing unlabeled [12C6,14N4]-arginine (R) and [12C6, 14N2]-lysine (K) 
amino acids, or in R10K8 “heavy” medium (Primacyt, no. DMEM-
15-LM015), containing labeled [13C6, 15N4]-arginine and [13C6, 
15N2]-lysine. These custom Dulbecco’s modified Eagle’s medium 
(DMEM) media were supplemented with 10% SILAC dialyzed 
fetal bovine serum (Primacyt, no. D-FCS100-DS1002) and 1% 
l-glutamine/penicillin/streptomycin solution (Sigma-Aldrich, no. 
G1146). Labeled cells were then transfected with either the pCMV6 
vector (Origene, no. PS100001) or with a pCMV6-LMTK3 plasmid 
encoding full-length LMTK3 (Origene, no. RC223140). After 24 hours, 
proteins were extracted and digested by filter-aided sample preparation.
HTRF chemical compound screening
The peptide phosphorylation activity of LMTK3 was measured 
using the proprietary biotin-tagged STK Substrate 1 (S1) from the 
HTRF KinEASE kit (Cisbio Bioassays, no. 62ST1PEB), according to 
the manufacturer’s instructions. Following analysis and optimization 
steps, the screening assays were carried out in low- volume, black 
384-well plates (Corning Life Sciences, MA), with a 10-l assay 
volume containing 3 M ATP, 50 nM STK-S1 biotin, and 25 ng per 
well of LMTK3 recombinant kinase domain (LMTK3cat). After in-
cubation at 37°C for 2 hours, the reaction was stopped with buffered 
EDTA, which contained the detection reagents, streptavidin-XL665, 
and the STK-antibody labeled with Eu3+-cryptate. The resulting 
TR-FRET signal, calculated as the fluorescence ratio at 665/620 nm, 
was read on an Envision and was proportional to the level of phos-
phorylation of the peptide. A library of 28,716 kinase inhibitor- 
biased compounds screened against LMTK3cat were initially tested 
at a single concentration (20 M), and the % of inhibition of 
the phosphorylation of STK-S1 peptide was determined. Further 
hit confirmation of the top 868 compounds showing >50% mean 
inhibition was done (20 M, in duplicate). Last, potency and 
LC-MS purity analysis of the top 160 inhibitors (>50% inhi-
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and the IC50 values were calculated. All the 28,716 compounds 
used for the screening were selected considering Lipinski’s rule of 
five properties (175 < MW (molecular weight) ≤ 500, AlogP ≤ 5, 
ACC (hydrogen bond acceptors) ≤ 10, Don ≤ 5, TPSA (topological 
polar surface area) ≤ 140).
Kinase inhibitor competition binding assay
The selectivity profiling of C28 kinase inhibitor at 5 M was ana-
lyzed using DiscoverX KINOMEscan competition binding assay 
against a panel of 456 kinases (www.discoverx.com).
Differential scanning fluorimetry
DSF was performed using Roche LightCycler 96 reverse transcrip-
tion polymerase chain reaction instrument with excitation and 
emission wavelengths set to 533 and 572 nm, respectively. Solutions 
comprising 16 l of 5.4 M LMTK3cat in 200 mM tris buffer (pH 
8.0), 200 mM NaCl, and 4 l of 50× SYPRO orange (Sigma-Aldrich) 
and 0.2 l of either dimethyl sulfoxide (DMSO) or C28 in DMSO 
(final concentration of 10 Μ C28, 1% (v/v) DMSO, 4.3 Μ LMTK3, 
and 10× SYPRO orange). The temperature range spanned from 25° to 
80°C at a scan rate of 1°C/min. Data analysis was performed in 
LightCycler 96 (v1.1) software using the melting curve analysis 
and Tm values were determined as the first negative derivative of 
the fluorescence with respect to the temperature.
CD spectroscopy
CD spectroscopy was performed using a Jasco J instrument. Tem-
perature was increased from 20° to 90°C at an increment of 1°C/min, 
and data points were acquired every 0.2°C by monitoring a wave-
length of 230 nm. For thermal stability experiments, LMTK3cat 
samples of 5.4 Μ in 200 mM tris buffer (pH 8.0) and 200 mM NaCl 
were treated with either DMSO 0.4% (v/v) or 8.3 Μ C28 in DMSO 
(0.4%) to a total volume of 120 l in 0.1-cm cuvettes. Data analysis 
was performed in GraphPad Prism (8) by fitting data in the transi-
tion region to a Boltzmann sigmoidal. Apparent Tm values were de-
termined as the point in which the transition was 50% complete.
Proteasome inhibition assay
To test whether LMTK3 is degraded by the proteasome upon C28 
exposure, cells were treated with 10 Μ of the proteasome inhibitor 
MG132 (or DMSO) for 4 hours before incubation with 10 Μ C28 
(or DMSO). Cells were lysed in modified radioimmunoprecipitation 
assay (RIPA) buffer [50 mM tris-HCl (pH 7.5), 150 mM NaCl, 1% 
sodium deoxycholate, 1% NP-40 alternative, 0.02% SDS containing 
protease, and phosphatase inhibitors (Roche Diagnostics GmbH, 
no. 11697498001 and no. 4906845001)] at the indicated time points. 
Following centrifugation at 17,000g for 30 min, the supernatant was 
collected as the soluble protein fraction. For collection of the insol-
uble protein, the remaining pellet was resuspended in modified RIPA 
buffer and sonicated for 10 s at 4°C using an MSE Soniprep 150.
Isothermal titration calorimetry
Proteins were dialyzed overnight into 20 mM tris (pH 7.5) containing 
5 mM NaCl and 1 mM EDTA. The heat of interaction was mea-
sured on an ITC200 (isothermal titration calorimeter 200) micro-
calorimeter (Microcal), with a cell volume of 200 l, under the 
same buffer conditions, but containing 2% DMSO and at 30°C. 
Typically, aliquots of 0.2 mM C28 was injected into 20 M intact 
HSP90. Heat of dilution was determined in a separate experiment 
by diluting protein into buffer, and the corrected data were fitted 
using a nonlinear least-squares curve-fitting algorithm (Microcal 
Origin) with three floating variables: stoichiometry, binding constant, 
and change in enthalpy of interaction.
Microscale thermophoresis
Purified LMTK3cat was labeled with an NHS-647 red dye (Nanotemper 
Technologies) following the manufacturer’s protocol. Purified CDC37 
or HSP27 (Abcam, no. ab48740) were serially diluted from 10 M in 
MST buffer (Nanotemper Technologies) supplemented with 0.05% 
Tween 20 before addition of labeled LMTK3 (50 nM). Samples were 
centrifuged at 12,000g for 5 min before loading into premium coated 
capillaries. Where specified, C28 (20 M, 0.4% DMSO) was added 
to LMTK3 before mixing with CDC37. MST measurements were 
taken with a Monolith NT.115 system using MO control software at 
21°C using 20% excitation power and 60% MST power. Data were 
analyzed using MO affinity software (Nanotemper Technologies).
Animal experiments
For xenograft generation, MDA-MB-231 cells (1 × 106) were injected 
subcutaneously into the left and right flank of 4- to 5-week-old NSG 
mice (nonobese diabetic–scidIL-2Rnull, the Jackson laboratory). 
Once tumors were palpable (approximately 0.4 to 0.5 cm in diameter), 
mice started a 3-week treatment by oral gavage daily, with one break 
per week. The treatment groups received either vehicle (5% dextrose/
PEG400 in a 1:1 ratio) or C28. To prepare the formulation, C28 was 
first dissolved in the necessary volume of PEG400, vortexed for 1 min, 
and then sonicated for 30 min at 40°C. Next, 5% dextrose solution 
in water was added to the formulation under vigorous vortexing. 
Tumors were monitored twice weekly by caliper measurements. In 
total, three mice died during the treatment (C28-treated animals).
For the MDA-MB-231-Luc xenograft experiment, 2 × 106 MDA-
MB-231-Luc cells were suspended in 50 l of 1× phosphate-buffered 
saline (PBS) and 50 l of Matrigel (1:1 ratio) and injected subcuta-
neously into the flanks of 5-week-old female NU/J homozygous mice 
(the Jackson laboratory, Maine, USA). MDA-MB-231-Luc cells 
(before injection) and the tumor implanted mice were imaged im-
mediately after cell injection using d-luciferin (Promega, WI, USA) 
dissolved in PBS and injected intraperitoneally at a dose of 1.5 mg 
per mouse, 15 min before measuring luminescence using IVIS 100 
bioluminescence/optical imaging system (Xenogen Corporation, CA, 
USA). Mice were monitored daily for any discomfort, tumor growth, 
and body weight. Once the tumors reached approximately 1 cm in 
size, mice were randomly divided into three groups: (i) vehicle: 5% 
dextrose/PEG400 25%:75%, v/v (n = 6); (ii) C28: 10 mg/kg (n = 6); 
and (iii) C28: 30 mg/kg (n = 5). The animals were imaged before 
the treatment started (day 0 of the treatment) to measure the 
tumor growth. Treatment was given for 21 days daily through oral 
gavage. Mice were imaged on days 14 and 21 after treatment. 
The tumor growth (%) increase for each mouse was calculated on 
the basis of the luminescence values at day 0 (randomization) and 
day 21.
MMTV-Neu mice were treated by oral gavage daily for a total of 
19 days, as soon as tumors were palpable. The treatment groups re-
ceived either vehicle (5% dextrose/PEG400 in a 1:1 ratio) or C28. Tu-
mors were monitored twice weekly by caliper measurements. Tumor 
volumes were calculated using the following formula: V = a × b2/2, 
where “a” is the largest diameter and “b” is the smallest. All animal 
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regulations and were approved by the BRFAA (Biomedical Research 
Foundation of the Academy of Athens) ethical committee.
PK parameters: Calculated per oral bioavailability (F%) for C28 
was 130% (based on the complete set of data from the 1 mg/kg 
intravenous group). Possible reasons for observing F% higher than 
100% with certain compounds and PK conditions include “non-
linear PK” (metabolic saturation) at nonequal intravenous and oral 
doses and enterohepatic recirculation. The first possibility appears 
to be the case since the calculation based on the incomplete set of 
data from the 5 mg/kg group gives a more realistic 54% number for 
peroral bioavailability.
Hematoxylin and eosin and IHC staining
Paraffin-embedded sections were deparaffinized and subjected to 
hematoxylin and eosin staining or IHC analysis using standard 
techniques. Heat-induced antigen retrieval was performed with citrate 
buffer (pH 6) using a pressure cooker before the IHC staining. The 
LMTK3 antibody (ab110516) was used at a concentration of 10 g/ml. 
The secondary antibody (Cell Signaling) was horseradish peroxidase– 
conjugated and was detected with DAB (Vector Laboratories). 
Stained IHC sections were counterstained with Mayer’s hematoxylin.
Chemical methods and synthesis procedures
Solvents were used as purchased including deuterated solvents for 
nuclear magnetic resonance (NMR) use. NMR spectra were recorded 
on a Varian NMR 600 (1H 600 MHz; 13C {1H} 151 MHz). Chemical 
shifts are reported in parts per million. Spectra are referenced to the 
corresponding protic solvent (1H) or signals of the solvent (13C). 
The progress of reactions was monitored by thin-layer chroma-
tography using commercially available glass silica gel plates (60 Å, 
F254). The mobile phase was usually a solvent mixture, and the 
visualization was undertaken using ultraviolet (UV) light. Chromato-
graphic purifications were carried out on an ISCO CombiFlash Rf75 
or 150 PSI purification unit and gel columns. LC-MS purity analyses 
were undertaken using a 5-m C18 110-Å column. Percent purity 
analysis was performed using a 30-min method in water/acetonitrile 
with 0.1% formic acid (5 min at 5%, 5 to 95% over 20 min, and 
5 min at 95%) with the UV set to 254 nm. High-resolution mass 




A mixture of 3-bromo-6-chloroimidazo[1,2-b]pyridazine (2.00 g, 
8.60 mmol), potassium phosphate (5.48 g, 25.80 mmol), 3-(trifluo-
romethoxy)phenylboronic acid (1.86 g, 9.30 mmol), water (0.77 ml, 
43.00 mmol), and anhydrous 1,4-dioxane (30 ml) was degassed 
under argon for 30 min. To the mixture was added [1,1′-bis 
(diphenylphosphino)ferrocene]dichloropalladium(II).CH2Cl2 
(352 mg, 0.43 mmol), and the resulting mixture was heated to 60°C 
for 16 hours under an argon atmosphere. The resulting mixture was 
cooled to ambient temperature, filtered through Celite, and concen-
trated under reduced pressure to give a dark orange gum (3.6 g). 
The resulting residue was purified by automated flash column chro-
matography (n-hexane/ethyl acetate, 100:0 to 0:100, 100 g of SiO2). 
The appropriate fractions were combined and concentrated under 
reduced pressure to give 6-chloro-3-(3-(trifluoromethoxy)phenyl)
imidazo[1,2-b]pyridazine (C28-Int) as a pale yellow solid (2.32 g, 
86%). LC-MS [UV, electrospray ionization (ESI)] Rt = 20.37 min, 
[M-H] + mass/charge ratio (m/z) = 313.9, 96% purity. 1H-NMR 
(600 MHz, d6 −DMSO):  = 8.46 (1H, s), 8.34 (1H, d, J = 9.4 Hz), 
8.17 (1H, s), 8.15 (1H, d, J = 8.0 Hz), 7.69 (1H, m), 7.48 (1H, d, J = 
9.5 Hz), and 7.42 (1H, d, J = 8.3 Hz).
Preparation of 6-(pyridin-4-yl)-3-(3-(trifluoromethoxy)
phenyl)imidazo[1,2-b]pyridazine (C28)
A mixture of 6-chloro-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]
pyridazine (980 mg, 3.13 mmol), 4-pyridinylboronic acid (578 mg, 
4.70 mmol), cesium carbonate (3.06 g, 9.39 mmol), anhydrous 
1,4-dioxane (15 ml), and water (5 ml) was degassed under argon for 
30 min. To the mixture was added [1,1′-bis(diphenylphosphino)
ferrocene]dichloropalladium(II).CH2Cl2 (128 mg, 0.157 mmol), and 
the resulting mixture was heated to 150°C under microwave irradi-
ation for 1 hour. To the resulting mixture was added ethyl acetate 
(20 ml) and water (20 ml). The resulting biphasic mixture was sep-
arated, and the aqueous phase was extracted with ethyl acetate (3 × 
20 ml). To the combined organic extracts was added 2 M aqueous 
HCl (10 ml), and the resulting mixture separated. The resulting 
organic phase was extracted with 2 M aqueous HCl (10 ml). The 
combined aqueous extracted were basified by the slow addition 
of saturated aqueous NaHCO3. To the mixture was added ethyl 
acetate (25 ml), and the resulting biphasic mixture separated. The 
aqueous phase was extracted with ethyl acetate (2 × 25 ml), and the 
combined organic extracts were washed with brine (50 ml), dried 
over anhydrous MgSO4, filtered, and concentrated under reduced 
pressure to give a dark yellow solid (1.3 g). The resulting residue 
was purified by automated column chromatography (ethyl acetate/
methanol, 100:0 to 75:25, 45 g of SiO2) followed by reverse-phase 
chromatography [water (+0.1% formic acid)/acetonitrile (+0.1% 
formic acid), 95:5 to 5:95, 30 g of C18]. The appropriate fractions 
were combined and concentrated under reduced pressure to give 
6-(pyridin-4-yl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]
pyridazine (C28) as a bright yellow solid (910 mg, 82%). LC-MS 
(UV, ESI) Rt = 14.46 min, [M-H] + m/z = 356.9, 100% purity. 1H- 
NMR (600 MHz, d6 −DMSO):  = 8.81 (2H, d, J = 5.7 Hz), 8.50 (1H, s), 
8.43 (1H, d, J = 9.5 Hz), 8.36 (1H, s), 8.25 (1H, s), 8.11 to 8.08 (2H, m), 
8.03 (1H, d, J = 9.5 Hz), 7.71 (1H, m), and 7.42 (1H, m). 13C NMR 
(151 MHz, d6 −DMSO):  = 150.6, 149.2, 148.7, 142.3, 139.9, 135.0, 
130.9, 130.4, 126.9, 125.2, 121.0, 120.2, 118.2, and 116.1 (one carbon 
not observed). HRMS (ESI-[+H]) m/z: Calculated for C18H12F3N4O 
357.0958; found 357.0953.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/46/eabc3099/DC1
View/request a protocol for this paper from Bio-protocol.
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